(Reuters) – U.S. drugmaker AbbVie is betting on the potential of the body’s immune system to fight Alzheimer’s by signing a drug development deal worth more than $ 200 million with unlisted biotech company Alector.
Testosterone Suits Soar Past 2,500 As Legal Milestone Looms for AbbVie
October 30, 2015By
Sales of AbbVie’s embattled testosterone drug AndroGel fell in what was otherwise a strong quarter for the company. Now AbbVie is facing the selection of the bellwether cases to be tried next year involving men who believe they were harmed by the gel.
Forbes – Health
